Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.

As previously reported, BofA analyst Alec Stranahan upgraded Beam Therapeutics (BEAM) to Buy from Neutral with an unchanged price target of $42 ...

Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") of a class action securities ...

Beam Therapeutics BEAM has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives ...

Genomics encompasses the study of a complete set of genes, their work process, and their way of interacting with each other and the environment. While it incorporates elements of genetics, the primary ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...